Spotlight on Hematology

Credits: 1.00 CME / CNE / CPE
Expert Perspectives on Improving Treatment of Patients with B-cell Non Hodgkin Lymphomas
Thomas Witzig, MD
Rush University Medical Center

Expert Perspectives on Improving Treatment of Patients with B-cell Non Hodgkin Lymphomas

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: November 9, 2018
Expires: November 8, 2019
60 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved with the treatment of patients with B-cell lymphomas

Learning Objectives

After completing this program, participants should be able to:

  • Summarize current best-practice approaches for treatment of patients with different subtypes of indolent and aggressive B-cell non-Hodgkin lymphomas (NHLs)
  • Asses recent clinical advances and emerging treatment options for the management of B-cell NHLs, including next generation mAbs, BTK inhibitors, PI3K inhibitors, IMiDs, Bcl-2 inhibitors, and ongoing clinical trials
  • Evaluate patient, disease, and treatment-related considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs

Activity Description

This activity provides healthcare providers with much needed professional education on treatment algorithms; recent clinical advances, emerging treatments, and clinical trials; as well as considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs.

Faculty

Thomas E. Witzig, MD
Professor of Medicine Mayo Clinic College of Medicine
Co-PI, University of Iowa/Mayo Clinic Lymphoma SPORE
Deputy Director of Clinical Research, Mayo Clinic Cancer Center
Rochester, MN


Conflict of Interest Policy/Disclosure Statement

Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

It is the policy of the Rush University Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months.

The course directors, planners and faculty of this activity have the following relevant financial relationships to disclose.

Thomas E. Witzig, MD
Research Grant: Celgene, Novartis, Acerta - for research trial expenses, no personal money received
Consultant: Celgene (personally uncompensated)

Michaela Ryan, PhD
Nothing to disclose

Beth-Anne M. Christopher, MS, RN, CNL
Nothing to disclose

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-130-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Inc., Celgene Corp., Novartis, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., AbbVie, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions About the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Hematology Presentations

0.50 CME
Postgraduate Institute for Medicine
A Changing Paradigm: Addressing Unmet Needs in Hemophilia A

A Changing Paradigm: Addressing Unmet Needs in Hemophilia A

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: September 26, 2018
Expires: September 25, 2019
30 minutes to complete

Jointly Provided By

Postgraduate Institute for Medicine (PIM), in joint providership with RMEI Medical Education (RMEI)

Target Audience

US-based clinicians, including hematology and hematology/oncology and hematology/oncology nurse practitioners and PAs.

Learning Objectives

After engaging in this educational activity, participants will be able to:

  1. Differentiate efficacy and safety data between current, novel, and future therapies for treating patients with hemophilia A without inhibitors and integrate their use into practice
  2. Incorporate appropriate management of hemophilia A with inhibitors in the treatment paradigm, based on the efficacy and safety, and mechanisms of current, novel, and emerging therapies
  3. Describe the mechanisms of action of emerging and novel targets beyond factor VIII and how these may be integrated into the treatment of hemophilia, based on the pathophysiologic underpinnings of the disease
  4. Employ a strong patient-provider collaborative approach to managing patients with hemophilia A that includes recognition and management of quality of life issues in patients with hemophilia A, and incorporates shared decision making

Activity Description

This multi-activity CME curriculum is designed to meet your clinical needs in hemophilia A. The initial activity is interactive and fast-paced, allowing you to test your knowledge, practice through a series of questions including case vignettes, compare yourself to your peers, and find out what the experts have to say about new developments and unmet patient needs in hemophilia A.

Statement of Educational Need

An estimated 60% of patients with hemophilia A have the severe form of the disease, which often leads to recurrent bleeding episodes into the joints.1 Recurring joint bleeds can result in debilitating joint disease and chronic pain, which negatively impacts the quality of life of patients living with hemophilia and contributes to significant disability. Patients who have hemophilia A with inhibitors represent an area of unmet need, since they suffer from worse outcomes because their disease is more resistant to prophylaxis and treatments. Hematology providers are challenged to manage hemophilia A and are even more challenged to manage hemophilia A with inhibitors. They also need to remain current with new developments in the field that could dramatically improve patients’ outcomes. While adherence, outcomes, and satisfaction are improved in patients who are engaged and participate in their healthcare decisions, hematology providers may not actively engage in shared decision making with their patients.

Reference:
1. Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22(5 Suppl):s126-133.

Faculty

Steven W. Pipe, MD
Professor, Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, MI

Steven W. Pipe, MD, is a professor and the Laurence A. Boxer research professor of pediatrics and communicable diseases, as well as a professor of pathology at the University of Michigan, Ann Arbor, MI. Dr Pipe completed his undergraduate medical training and received his medical degree from the University of Toronto, Ontario, Canada. He completed his pediatric training at the McMaster University in Hamilton, Ontario, and his pediatric hematology and oncology training and fellowship in the Pediatric Scientist Development Program at the University of Michigan. Dr Pipe is certified by the American Board of Pediatrics in pediatric hematology/oncology.

Dr Pipe is the medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory at the University of Michigan. His clinical interests include bleeding and thrombotic disorders and congenital vascular anomalies. Dr Pipe also directs a basic research lab investigating coagulation factor VIII and the molecular mechanisms of hemophilia A.

Dr Pipe was awarded a Young Investigator Award from both the American Society of Pediatric Hematology and Oncology and the International Society on Thrombosis and Haemostasis, and a Faculty Scholar Award from the American Society of Hematology. He has been the recipient of the Leadership in Research Award from the National Hemophilia Foundation. Dr Pipe has served on the Board of Directors for the Hemostasis and Thrombosis Research Society, as chair of the Board of Directors for the American Thrombosis and Hemostasis Network, and is currently the Chair of the Medical and Scientific Advisory Committee to the National Hemophilia Foundation.

Steven W. Pipe, MD,has affiliations with Alnylam, Bayer, Biomarin, Bioverativ, Catalyst Biosciences, CSL Behring, DNArx, HEMA Biologics, Novo Nordisk, Pfizer, Roche/Genentech, Shire, Spark Therapeutics, and uniQure (Consulting Fees); Shire and Siemens (Contracted Research).


Conflict of Interest Policy/Disclosure Statement

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

YOUR FEEDBACK IS IMPORTANT!
Complete the Evaluation form for this activity and be entered into a drawing for a $100* Amazon Gift card.

*The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.
 
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an independent educational grant from Genentech.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME
Postgraduate Institute for Medicine
Experts-in-the-Hot Seat: Emerging Trends in Managing Hemophilia A

Experts-in-the-Hot Seat: Emerging Trends in Managing Hemophilia A

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: January 31, 2019
Expires: January 30, 2020
30 minutes to complete

Jointly Provided By

Postgraduate Institute for Medicine (PIM), in joint providership with RMEI Medical Education (RMEI).

Target Audience

US-based clinicians, including hematology and hematology/oncology and hematology/oncology nurse practitioners and PAs.

Learning Objectives

After engaging in this educational activity, participants will be able to:

  1. Differentiate efficacy and safety data between current, novel, and future therapies for treating patients with hemophilia A without inhibitors and integrate their use into practice
  2. Incorporate appropriate management of hemophilia A with inhibitors in the treatment paradigm, based on the efficacy and safety, and mechanisms of current, novel, and emerging therapies
  3. Describe the mechanisms of action of emerging and novel targets beyond factor VIII and how these may be integrated into the treatment of hemophilia, based on the pathophysiologic underpinnings of the disease
  4. Employ a strong patient-provider collaborative approach to managing patients with hemophilia A that includes recognition and management of quality of life issues in patients with hemophilia A, and incorporates shared decision-making

Activity Description

This multi-activity CME curriculum is designed to meet your clinical needs in hemophilia A. In this activity, you will hear insights from 3 hemophilia experts on the current management approach to hemophilia A without and with inhibitors, new developments in hemophilia A therapies, and ways to incorporate shared decision-making when treating patients with hemophilia A. In addition, you will have an opportunity to practice through a series of questions and compare yourself to your peers.

Statement of Educational Need

An estimated 60% of patients with hemophilia A have the severe form of the disease, which often leads to recurrent bleeding episodes into the joints.1 Recurring joint bleeds can result in debilitating joint disease and chronic pain, which negatively impacts the quality of life of patients living with hemophilia and contributes to significant disability. Patients who have hemophilia A with inhibitors represent an area of unmet need, since they suffer from worse outcomes because their disease is more resistant to prophylaxis and treatments. Hematology providers are challenged to manage hemophilia A and are even more challenged to manage hemophilia A with inhibitors. They also need to remain current with new developments in the field that could dramatically improve patients’ outcomes. While adherence, outcomes, and satisfaction are improved in patients who are engaged and participate in their healthcare decisions, hematology providers may not actively engage in shared decision-making with their patients.

Reference:
1. Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22(5 Suppl):s126-133.

Faculty

Steven W. Pipe, MD
Professor, Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, MI

Steven W. Pipe, MD, is a professor and the Laurence A. Boxer research professor of pediatrics and communicable diseases, as well as a professor of pathology at the University of Michigan, Ann Arbor, MI. Dr Pipe completed his undergraduate medical training and received his medical degree from the University of Toronto, Ontario, Canada. He completed his pediatric training at the McMaster University in Hamilton, Ontario, and his pediatric hematology and oncology training and fellowship in the Pediatric Scientist Development Program at the University of Michigan. Dr Pipe is certified by the American Board of Pediatrics in pediatric hematology/oncology.

Dr Pipe is the medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory at the University of Michigan. His clinical interests include bleeding and thrombotic disorders and congenital vascular anomalies. Dr Pipe also directs a basic research lab investigating coagulation factor VIII and the molecular mechanisms of hemophilia A.

Dr Pipe was awarded a Young Investigator Award from both the American Society of Pediatric Hematology and Oncology and the International Society on Thrombosis and Haemostasis, and a Faculty Scholar Award from the American Society of Hematology. He has been the recipient of the Leadership in Research Award from the National Hemophilia Foundation. Dr Pipe has served on the Board of Directors for the Hemostasis and Thrombosis Research Society, as chair of the Board of Directors for the American Thrombosis and Hemostasis Network, and is currently the Chair of the Medical and Scientific Advisory Committee to the National Hemophilia Foundation.

Steven W. Pipe, MD,has affiliations with Alnylam, Bayer, Biomarin, Bioverativ, Catalyst Biosciences, CSL Behring, DNArx, HEMA Biologics, Novo Nordisk, Pfizer, Roche/Genentech, Shire, Spark Therapeutics, uniQure (Consulting Fees); Shire, Siemens (Contracted Research).


Rebecca Kruse-Jarres, MD, MPH
Medical Director, Bloodworks Northwest
Washington Center for Bleeding Disorders
Seattle, WA

Rebecca Kruse-Jarres, MD, MPH, is the director of the Washington Center for Bleeding Disorders (WACBD) at Bloodworks Northwest in Seattle, WA. She earned her medical degree at Tulane University in New Orleans, LA where she also received a master’s degree in public health and tropical medicine. She completed her residency in internal medicine and fellowship in hematology/oncology at Tulane, became faculty in the Department of Medicine, and served as the associate director of the Louisiana Center for Bleeding and Clotting Disorders. Dr Kruse-Jarres holds faculty appointments in both medicine and pediatrics at the University of Washington and cares for ~900 individuals with inherited bleeding disorders across the state of Washington. She is board-certified in internal medicine, medical oncology, and hematology.

Dr Kruse-Jarres is nationally and internationally known for her work with inhibitors in acquired and congenital hemophilia and has been actively involved with several national and international clinical trials studying new treatments for this patient population. Dr Kruse-Jarres is the president of the Hemostasis and Thrombosis Research Society. She has received many honors and awards, including Best Doctors in America, Louisiana’s Top Doctors, and the Greater New Orleans (GNO) Health and Service Corps Award.

Rebecca Kruse-Jarres, MD, MPH, has affiliations with Grifols, Roche, Shire (Consulting Fees); Roche, Shire (Speakers’ Bureaus).


Cindy A. Leissinger, MD
Professor of Medicine, Clinical Professor of Pathology and Pediatrics
Director, Louisiana Center for Bleeding and Clotting Disorders
Chief, Section of Hematology/Oncology
Tulane University School of Medicine
New Orleans, LA

Cindy A. Leissinger, MD, is currently a professor of medicine and a clinical professor of pediatrics and pathology at Tulane University in New Orleans, LA. She serves as the chief of the Hematology/Oncology Section and is also the director of the Louisiana Center for Bleeding and Clotting Disorders. Dr Leissinger received her medical degree from Tulane University School of Medicine. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at the National Institutes of Health in Bethesda, MD, and a clinical fellowship in hematology and medical oncology at Tulane. Dr. Leissinger is board-certified in internal medicine and hematology.

Dr Leissinger is actively involved in the American Society of Hematology, the International Society on Thrombosis and Haemostasis, and the Hemostasis and Thrombosis Research Society. In addition to caring for patients with bleeding and clotting disorders, Dr Leissinger oversees an active research program. She participates in several clinical research groups and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in factor VIII inhibitor development and management.

Dr Leissinger has many peer-reviewed publications in numerous journals including Blood,The New England Journal of Medicine,Haemophilia, and Thrombosis Research.

Cindy A. Leissinger, MD, has affiliations with Bayer, CSL Behring, Genentech, HemaBiologics, Kedrion, NovoNordisk, Pfizer, Shire (Advisory Boards); BioMarin, Genentech (Contracted Research).


Conflict of Interest Policy/Disclosure Statement

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Media

Internet

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

Complete the evaluation form and participants will be entered into a drawing to win a $100 Amazon Gift Card!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE / CPE
AXIS
Managing Metastatic NSCLC: Strategies for Treatment Selection

Managing Metastatic NSCLC: Strategies for Treatment Selection

Start

Activity Details

Free CME/CPE/CNE
0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: June 11, 2018
Expires: June 10, 2019
30 minutes to complete

Provided By

Target Audience

This activity is intended for community oncologists, nurses, pharmacists, and other healthcare professionals who manage NSCLC.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Summarize the indications, efficacy, and safety profiles of recently approved therapies for NSCLC, including EGFR and checkpoint inhibitors
  • Devise treatment selection and drug sequencing strategies that incorporate newer therapies for patients with metastatic NSCLC
  • Identify potential toxicities associated with therapies used for NSCLC

Activity Description

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the treatment of NSCLC so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices for their patients. AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on NSCLC.

Statement of Educational Need

The treatment of NSCLC has changed significantly as a result of the identification of clinically relevant biomarkers and the development of targeted therapies. Although patient outcomes have improved as a result of treatment advances, metastatic disease is still an important challenge. Knowledge and practice gaps can be seen in several aspects of the treatment of metastatic NSCLC, such as how to integrate new therapies into practice, manage toxicities associated with new therapies, and make best use of a shared decision-making approach to treatment.

Faculty

David S. Ettinger, MD, FACP, FCCP
Alex Grass Professor of Oncology
Professor of Medicine
Professor of Radiation Oncology and Molecular Radiation Sciences
The Johns Hopkins University School of Medicine
Baltimore, Maryland


Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

David S. Ettinger, MD, FACP, FCCP, serves(d) as an advisor/consultant for:
BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb Co; Eli Lilly and Co; Genentech, Inc; Golden Biotechnology Corporation; and Guardant Health, Inc.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda-Gracie-King, MS; Jocelyn Timko, BS; Kristen Baileys, RN, MSN, CRNP, OCN; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Stephanie Sutphin, PharmD,hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education credit. JA4008106-0000-18-017-H01-P

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. Pharmacists – your record will be loaded to CPE Monitor.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives on Improving Treatment of Patients with B-cell Non Hodgkin Lymphomas

Expert Perspectives on Improving Treatment of Patients with B-cell Non Hodgkin Lymphomas

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: November 9, 2018
Expires: November 8, 2019
60 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved with the treatment of patients with B-cell lymphomas

Learning Objectives

After completing this program, participants should be able to:

  • Summarize current best-practice approaches for treatment of patients with different subtypes of indolent and aggressive B-cell non-Hodgkin lymphomas (NHLs)
  • Asses recent clinical advances and emerging treatment options for the management of B-cell NHLs, including next generation mAbs, BTK inhibitors, PI3K inhibitors, IMiDs, Bcl-2 inhibitors, and ongoing clinical trials
  • Evaluate patient, disease, and treatment-related considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs

Activity Description

This activity provides healthcare providers with much needed professional education on treatment algorithms; recent clinical advances, emerging treatments, and clinical trials; as well as considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs.

Faculty

Thomas E. Witzig, MD
Professor of Medicine Mayo Clinic College of Medicine
Co-PI, University of Iowa/Mayo Clinic Lymphoma SPORE
Deputy Director of Clinical Research, Mayo Clinic Cancer Center
Rochester, MN


Conflict of Interest Policy/Disclosure Statement

Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

It is the policy of the Rush University Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months.

The course directors, planners and faculty of this activity have the following relevant financial relationships to disclose.

Thomas E. Witzig, MD
Research Grant: Celgene, Novartis, Acerta - for research trial expenses, no personal money received
Consultant: Celgene (personally uncompensated)

Michaela Ryan, PhD
Nothing to disclose

Beth-Anne M. Christopher, MS, RN, CNL
Nothing to disclose

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-130-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Inc., Celgene Corp., Novartis, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., AbbVie, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions About the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME
University of Nebraska Medical Center
The Next Steps in CAR T-Cell Therapy for the Treatment of Patients With Lymphoma

The Next Steps in CAR T-Cell Therapy for the Treatment of Patients With Lymphoma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credits
Released: August 31, 2018
Expires: August 31, 2019
20 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Target Audience

The target audience for this activity is for community and academic medical oncologists, hematologists, advanced practitioners, and other clinicians who treat patients with lymphoma.

Learning Objectives

After completing this activity, participants should be better able to:

  • Review clinical trial data that led to approval of CAR T-cell–based therapies for the treatment of patients with lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with lymphoma, including various combination strategies being examined
  • Develop strategies to mitigate adverse events often encountered with the use of CAR T-cell therapy, including cytokine release syndrome and neurotoxicity

Activity Description

Expert Insights is an interview involving 2 world renowned experts actively engaged in treatment of patients with lymphoma. This discussion features expert summary and interpretation of data presented during the 2018 Pan Pacific Lymphoma Conference in Hawaii, as well as provide guidance on the optimal use of current and emerging therapies.

Statement of Educational Need

CD19-targeted CAR T cells have emerged as a highly effective therapy in patients with NHL. However, multiple CAR T-cell technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with aggressive NHL need expert guidance to evaluate clinical data on CAR T-cell therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Faculty

Julie M. Vose, MD, MBA - Moderator
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Grants/Research Support: Acerta Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Kite Pharma, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Seattle Genetics, Inc.

Consultant Fees, Honorarium: AbbVie Inc., Epizyme, Inc., Karyopharm Therapeutics, Legend Pharmaceuticals, Novartis, Roche, Sandoz, Vaniam Group LLC


Sattva S. Neelapu, MD
Professor
Deputy Department Chair ad interim
Director of Laboratory and Translational Research
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Research Support, Advisor: Acerta Pharma, Bristol-Myers Squibb Company, Cellectis, Gilead, Karus, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Poseida

Consultant, Advisor: Celgene Corporation, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Unum Therapeutics


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

Educational grant support provided by Celgene Corporation and Kite, A Gilead Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
meetings@bioascend.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
University of Nebraska Medical Center
The Time is Now: Focusing on New and Emerging Therapies for Improving Patient Outcomes in AML

The Time is Now: Focusing on New and Emerging Therapies for Improving Patient Outcomes in AML

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: August 20, 2018
Expires: August 20, 2019
45 minutes to complete

Accredited By

University of Nebraska Medical Center, Center for Continuing Education

Provided By


This activity is co-provided by University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc.

Target Audience

This program is intended for hematologists, medical oncologists, health system pharmacists, oncology nurses, nurse practitioners, physician assistants, and other healthcare providers involved in the care of patients with AML.

Learning Objectives

Upon completion of this educational activity, participants should be better able to:

  • Describe the pathophysiology of AML and identify potential therapeutic targets
  • Summarize current clinical trial evidence regarding the efficacy and safety of new and emerging therapies for AML
  • Outline an approach to AML treatment selection that is tailored based upon individual patient characteristics

Activity Description

Despite recent advances in understanding of the pathophysiology of AML and a corresponding expansion of targeted treatment modalities, the care of individuals with the disease remains a significant challenge in current clinical practice. The following program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote accurate disease classification and risk assessment, and personalized treatment for patients with AML, including older individuals and those with relapsing or refractory disease.

Faculty

Jorge E. Cortes, MD
Jorge E. Cortes, MD
Jane and John Justin Distinguished Chair in Leukemia Research
Section Chief of AML & CML
Deputy Chairman
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Richard M. Stone, MD
Richard M. Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Director, Adult Acute Leukemia Program
Dana-Farber Cancer Institute
Boston, Massachusetts


Conflict of Interest Policy/Disclosure Statement

The University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by The University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Jorge E. Cortes, MD, has no real or apparent conflicts of interest to report.

Richard M. Stone, MD
Consultant: Abbvie, Agios, Amgen, Argenix, Arog, Astellas, Celator, Celgene, Cornerstone, Fujifilm, Janssen, Jazz, Juno, Karyopharm, Merck, Novartis, Ono, Orsenix, Otsuka, Pfizer
Research: Agios, Arog, Novartis
Board Member: Actinium
Steering Committee: Celgene

Patima Tanapat, PhD, has no real or apparent conflicts of interest to report.

Accreditation Statement for Physicians

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of August 20, 2018 through August 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Nebraska Medical Center, Center for Continuing Education, Integrity Continuing Education, Inc. and Pfizer do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about this activity, please contact the University of Nebraska Medical Center, Center for Continuing Education at (402) 559-4152 or via email at conted@unmc.edu.